文献速递神经肿瘤

抗抑郁药酸性鞘磷脂酶抑制活性对胶质母细胞瘤生存影响的回顾性分析

Retrospective analysis of the impact of antidepressants with anti-acid sphingomyelinase activity on survival of patients with glioblastoma.
PubMed 文献 · J Neurooncol · 2026-01-03

该研究回顾性分析2015至2024年单中心胶质母细胞瘤患者,评估酸性鞘磷脂酶抑制剂(ASMi)对总生存的影响,采用Kaplan-Meier分析和Cox比例风险模型并调整年龄、性别、肿瘤位置、TTF使用和MGMT启动子甲基化状态,辅以倾向评分匹配。结果显示ASMi整体使用与OS无显著关联(HR=0.81,95%CI 0.55–1.2,p=0.26),但氟西汀单药显著改善OS(HR=0.36,95%CI 0.15–0.9,p=0.03),且在多变量分析和倾向匹配队列中持续显著。

要点

  • ASMi整体使用未显著改善GBM患者总生存。
  • 氟西汀是唯一与OS改善显著相关的ASMi。
  • 氟西汀生存获益在调整及倾向匹配后仍显著。

核心结论

  • 氟西汀与胶质母细胞瘤患者生存改善相关,而其他ASMi及ASMi整体使用未显示此关联。
  • 氟西汀可能具有超出ASM抑制的独特抗肿瘤效应,值得进一步研究。

研究设计与样本

  • 单中心回顾性研究,纳入2015至2024年治疗的胶质母细胞瘤患者。
  • 采用Kaplan-Meier分析和Cox比例风险模型评估ASMi对总生存的影响,调整年龄、性别、肿瘤位置、TTF使用和MGMT启动子甲基化状态。
  • 进行倾向评分匹配以平衡基线差异。

主要发现

  • ASMi整体使用与OS无统计学显著获益(HR=0.81,95%CI 0.55–1.2,p=0.26)。
  • 氟西汀是唯一显著改善OS的ASMi(HR=0.36,95%CI 0.15–0.9,p=0.03)。
  • 氟西汀单药多变量分析(n=17 vs. 186对照)中生存获益仍显著(HR=0.38,95%CI 0.15–0.94,p=0.04)。
  • 调整后的倾向匹配队列中氟西汀效应持续(HR=0.20,95%CI 0.05–0.78,p=0.02)。
  • 年龄和MGMT启动子未甲基化状态与生存下降独立相关。

关键数值与推荐

  • ASMi整体使用OS:HR=0.81,95%CI 0.55–1.2,p=0.26。
  • 氟西汀OS:HR=0.36,95%CI 0.15–0.9,p=0.03。
  • 氟西汀多变量分析(n=17 vs. 186):HR=0.38,95%CI 0.15–0.94,p=0.04。
  • 氟西汀倾向匹配队列:HR=0.20,95%CI 0.05–0.78,p=0.02。

临床怎么用

  • 氟西汀可能与GBM患者生存改善相关,但证据来自回顾性研究,需前瞻性验证。
  • 其他ASMi或ASMi整体使用未显示生存获益,不应据此改变临床实践。

局限性

  • 回顾性单中心设计,样本量有限,尤其氟西汀组仅17例。
  • 可能存在未测量的混杂因素,倾向评分匹配不能完全消除偏倚。
  • 结果需外部验证和前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Glioblastoma (GBM) is the most common malignant primary brain tumor in adults and remains difficult to treat. Though still under investigation, acid sphingomyelinase (ASM) has been implicated in GBM lipid raft formation, which facilitates cancer signaling. We sought to verify if, and if so what kinds of ASM inhibitors (ASMis) improve outcomes in GBM. METHODS: We conducted a retrospective study of GBM patients treated between 2015 and 2024 at one academic center. ASMi impact on overall survival (OS) was assessed using Kaplan-Meier analysis and Cox proportional hazards models adjusting for age, sex, tumor location, use of tumor-treating fields (TTFs), and MGMT promoter methylation status. Propensity score matching was performed to account for baseline imbalances. RESULTS: ASMi use alone was not associated with a statistically significant OS benefit (HR = 0.81, 95% CI 0.55–1.2, p = 0.26). Stratifying by ASMi revealed fluoxetine as the only medication that significantly improved OS (HR = 0.36, 95% CI 0.15–0.9, p = 0.03). In a fluoxetine-only multivariate analysis (n = 17 vs. 186 controls), the survival benefit remained significant (HR = 0.38, 95% CI 0.15–0.94, p = 0.04). This effect persisted in the adjusted propensity-matched cohort (HR = 0.20, 95% CI 0.05–0.78, p = 0.02). Age and unmethylated MGMT promoter status were independently associated with decreased survival. CONCLUSION: Fluoxetine was associated with increased survival in GBM patients whereas other ASMis and ASMi use overall was not. These findings suggest that fluoxetine may have unique anti-tumor effects beyond ASM inhibition and justify further investigation.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Liu CM, Medeiros Geraldo LH, Xiao J, et al. Retrospective analysis of the impact of antidepressants with anti-acid sphingomyelinase activity on survival of patients with glioblastoma. J Neurooncol. 2026. PMID: 41483088. doi:10.1007/s11060-025-05388-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。